Schizophrenia is characterized by significant heterogeneity in outcome. The last decades have witnessed a significant interest in identifying factors that can moderate or influence clinical and functional outcomes in people with schizophrenia. One factor of particular interest is neurocognition, as performance on various measures of cognitive abilities, such as memory, attention, and executive functions, have been consistently related to functional outcome and, to a lesser extent, clinical outcome. This review aims to provide an up-to-date description of recent studies examining the association between neurocognition and clinical and (or) functional outcomes. In the first section, studies examining neurocognitive performance in relation to clinical outcome are examined. When clinical outcome is defined dichotomously (for example, comparing remitted and nonremitted), verbal memory performance consistently exhibits a strong association with clinical status, with the poor outcome group showing the largest deficits. In the second section, studies exploring the relation between neurocognition and various dimensions of functional outcome are reviewed. These dimensions include independent living, social functioning, and vocational functioning, among others. Again, a strong link between neurocognitive deficits and impairments in several aspects of functioning clearly emerges from this review. Finally, several measurement issues are discussed that pertain to the need to standardize definitions of clinical and (or) functional outcomes, the importance of defining cognitive domains consistently across studies, and distinguishing between one's competence to perform tasks and what one actually does in everyday life. Addressing these measurement issues will be key to studies examining the development of effective interventions targeting neurocognitive functions and their impact on clinical and functional outcomes.
WarnerR.Recovery from schizophrenia and the recovery model. Curr Opin Psychiatry. 2009;22(4):374–380.
2.
MenezesNMArenovichTZipurskyRB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006;36(10):1349–1362.
3.
TandonRNasrallahHAKeshavanMS. Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122(1–3):1–23.
4.
BowieCRLeungWWReichenbergA, Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):505–511.
5.
GreenMF. What are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry. 1996;153(3):321–330.
6.
GreenMFKernRSBraffDL, Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the “right stuff”? Schizophr Bull. 2000;26(1):119–136.
7.
JooberRRouleauGALalS, Neuropsychological impairments in neuroleptic-responder vs -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res. 2002;53(3):229–238.
8.
AddingtonJLerigerEAddingtonD.Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry. 2003;48(3):204–207.
9.
HoBCAndreasenNCNopoulosP, Progressive structural brain abnormalities and their relationship to clinical outcome: A longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 2003;60(6):585–594.
10.
HovingtonCLLepageM.Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Rev Neurother. 2012;12(1):53–69.
11.
BuchananRW. Persistent negative symptoms in schizophrenia: An overview. Schizophr Bull. 2007;33(4):1013–1022.
12.
AndreasenNCCarpenterWTJrKaneJM, Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449.
13.
EmsleyRChilizaBAsmalL, The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry. 2011;24(2):114–121.
14.
ShrivastavaAJohnstonMShahN, Redefining outcome measures in schizophrenia: Integrating social and clinical parameters. Curr Opin Psychiatry. 2010;23(2):120–126.
AlbertNBertelsenMThorupA, Predictors of recovery from psychosis analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years. Schizophr Res. 2011;125(2–3):257–266.
17.
LambertMKarowALeuchtS, Remission in schizophrenia: Validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci. 2010;12(3):393–407.
18.
HeinrichsRWZakzanisKK. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology. 1998;12(3):426–445.
19.
Mesholam-GatelyRIGiulianoAJGoffKP, Neurocognition in first-episode schizophrenia: A meta-analytic review. Neuropsychology. 2009;23(3):315–336.
20.
MarderSRFentonW.Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004;72(1):5–9.
21.
GreenMFNuechterleinKHGoldJM, Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56(5):301–307.
22.
RanganathCMinzenbergMJRaglandJD. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol Psychiatry. 2008;64(1):18–25.
23.
SzymanskiSMasiarSMayerhoffD, Clozapine response in treatment-refractory first-episode schizophrenia. Biol Psychiatry. 1994;35(4):278–280.
24.
KopalaLCFredriksonDGoodKP, Symptoms in neuroleptic-naive, first-episode schizophrenia: Response to risperidone. Biol Psychiatry. 1996;39(4):296–298.
25.
SangerTMLiebermanJATohenM, Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry. 1999;156(1):79–87.
26.
EmsleyRA. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Risperidone Working Group. Schizophr Bull. 1999;25(4):721–729.
27.
YapHLMahendranRLimD, Risperidone in the treatment of first episode psychosis. Singapore Med J. 2001;42(4):170–173.
28.
AmmingerGPReschFMutschlechnerR, Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur Child Adolesc Psychiatry. 1997;6(4):212–218.
29.
LibermanRKopelowiczAVentureJ, Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002;14:256–272.
30.
ManchandaRMallaAHarricharanR, EEG abnormalities and outcome in first-episode psychosis. Can J Psychiatry. 2003;48(11):722–726.
31.
LiebermanJAPhillipsMGuH, Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995–1003.
32.
GorwoodPPeuskensJ.Setting new standards in schizophrenia outcomes: Symptomatic remission 3 years before versus after the Andreasen criteria. Eur Psychiatry. 2012;27(3):170–175.
33.
NuechterleinKHBarchDMGoldJM, Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72(1):29–39.
34.
BodnarMMallaAJooberR, Cognitive markers of short-term clinical outcome in first-episode psychosis. Br J Psychiatry. 2008;193(4):297–304.
35.
HelldinLKaneJMKarilampiU, Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res. 2006;40(8):738–345.
36.
BodnarMHarveyP-OMallaA, The parahippocampal gyrus as a neural marker of early remission in first-episode psychosis: A voxel-based morphometry study. Clin Schizophr Relat Psychoses. 2011;4(4):217–228.
37.
MeestersPDSchouwsSStekM, Cognitive impairment in late life schizophrenia and bipolar I disorder. Int J Geriatr Psychiatry. 2013;28(1):82–90; Epub 2012 Mar 12.
38.
HolthausenEAWiersmaDCahnW, Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res. 2007;149(1–3):71–80.
39.
HoferABodnerTKaufmannA, Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychol Med. 2011;41(10):2131–2139.
40.
BrissosSDiasV VBalanza-MartinezV, Symptomatic remission in schizophrenia patients: Relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res. 2011;129(2–3):133–136.
41.
EberhardJLevanderSLindstromE.Remission in schizophrenia: Analysis in a naturalistic setting. Compr Psychiatry. 2009;50(3):200–208.
42.
Yun daYHwangSSKimY, Impairments in executive functioning in patients with remitted and non-remitted schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1148–1154.
43.
LiCTSuTPChouYH, Symptomatic resolution among Chinese patients with schizophrenia and associated factors. J Formos Med Assoc. 2010;109(5):378–388.
44.
CiudadAAlvarezEBobesJ, Remission in schizophrenia: Results from a 1-year follow-up observational study. Schizophr Res. 2009;108(1–3):214–222.
45.
MontreuilTBodnarMBertrandMC, Social cognitive markers of short-term clinical outcome in first-episode psychosis. Clin Schizophr Relat Psychoses. 2010;4(2):105–114.
46.
PietrzakRHOlverJNormanT, A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009;31(7):848–859.
47.
MaruffPThomasECysiqueL, Validity of the CogState brief battery: Relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2):165–178.
48.
NuechterleinKHGreenMFKernRS, The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203–213.
49.
KernRSNuechterleinKHGreenMF, The MATRICS Consensus Cognitive Battery, part 2: Co-norming and standardization. Am J Psychiatry. 2008;165(2):214–220.
50.
ChwastiakLARosenheckRAMcEvoyJP, Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatr Serv. 2006;57(8):1102–1109.
51.
TiihonenJLonnqvistJWahlbeckK, 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627.
52.
EvansJDHeatonRKPaulsenJS, The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry. 2003;53(5):422–430.
53.
HarveyPDSukhodolskyDParrellaM, The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. Schizophr Res. 1997;27(2–3):211–228.
54.
VelliganDIBow-ThomasCCMahurinRK, Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?J Nerv Ment Dis. 2000;188(8):518–524.
55.
FriedmanJIHarveyPDColemanT, Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: A comparison with Alzheimer's disease and normal aging. Am J Psychiatry. 2001;158(9):1441–1448.
56.
HegartyJDBaldessariniRJTohenM, One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):1409–1416.
57.
MausbachBTHarveyPDGoldmanSR, Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007;33(6):1364–1372.
58.
BowieCRFallonCHarveyPD. Convergence of clinical staff ratings and research ratings to assess patients with schizophrenia in nursing homes. Psychiatr Serv. 2006;57(6):838–843.
59.
KeefeRSPoeMWalkerTM, The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. J Clin Exp Neuropsychol. 2006;28(2):260–269.
60.
HeinrichsRWAmmariNMilesAA, Cognitive performance and functional competence as predictors of community independence in schizophrenia. Schizophr Bull. 2010;36(2):381–387.
61.
ShamsiSLauALenczT, Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011;126(1–3):257–264.
62.
CaplanBSchuttRKTurnerWM, Change in neurocognition by housing type and substance abuse among formerly homeless seriously mentally ill persons. Schizophr Res. 2006;83(1):77–86.
63.
GuptaMBassettEIfteneF, Functional outcomes in schizophrenia: Understanding the competence-performance discrepancy. J Psychiatr Res. 2012;46(2):205–211.
64.
VelliganDIWeidenPJSajatovicM, The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46; quiz 47–48.
65.
HeinrichsRWGoldbergJOMilesAA, Predictors of medication competence in schizophrenia patients. Psychiatry Res. 2008;157(1–3):47–52.
66.
PerkinsDOGuHWeidenPJ, Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106–113.
67.
SmithTEHullJWIsraelLM, Insight, symptoms, and neurocognition in schizophrenia and schizoaffective disorder. Schizophr Bull. 2000;26(1):193–200.
68.
KurtzMMTolmanA.Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: What is their relationship?Schizophr Res. 2011;127(1–3):157–162.
69.
McGurkSRMueserKTWallingD, Cognitive functioning predicts outpatient service utilization in schizophrenia. Ment Health Serv Res. 2004;6(3):185–188.
70.
JohansenRHestadKIversenVC, Cognitive and clinical factors are associated with service engagement in early-phase schizophrenia spectrum disorders. J Nerv Ment Dis. 2011;199(3):176–182.
71.
BrekkeJSHoeMGreenMF. Neurocognitive change, functional change and service intensity during community-based psychosocial rehabilitation for schizophrenia. Psychol Med. 2009;39(10):1637–1647.
72.
HarleyEWBoardmanJCraigT.Friendship in people with schizophrenia: A survey. Soc Psychiatry Psychiatr Epidemiol. 2012;47(8):1291–1299; Epub 2011 Oct 8.
73.
MacCabeJHKoupilILeonDA. Lifetime reproductive output over two generations in patients with psychosis and their unaffected siblings: The Uppsala 1915–1929 Birth Cohort Multigenerational Study. Psychol Med. 2009;39(10):1667–1676.
74.
CorriganPWNelsonDR. Factors that affect social cue recognition in schizophrenia. Psychiatry Res. 1998;78(3):189–196.
75.
ZanelloAPerrigLHugueletP.Cognitive functions related to interpersonal problem-solving skills in schizophrenic patients compared with healthy subjects. Psychiatry Res. 2006;142(1):67–78.
76.
DochertyNM. Cognitive impairments and disordered speech in schizophrenia: Thought disorder, disorganization, and communication failure perspectives. J Abnorm Psychol. 2005;114(2):269–278.
77.
Shamay-TsoorySGShurSHarariH, Neurocognitive basis of impaired empathy in schizophrenia. Neuropsychology. 2007;21(4):431–438.
78.
SerperMBeechDRHarveyPD, Neuropsychological and symptom predictors of aggression on the psychiatric inpatient service. J Clin Exp Neuropsychol. 2008;30(6):700–709.
79.
SchonUKDenhovAToporA.Social relationships as a decisive factor in recovering from severe mental illness. Int J Soc Psychiatry. 2009;55(4):336–347.
80.
BowieCRReichenbergAPattersonTL, Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006;163(3):418–425.
81.
McClureMMBowieCRPattersonTL, Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: Evidence for specificity of relationships?Schizophr Res. 2007;89(1–3):330–338.
82.
St GermainSAKurtzMMPearlsonGD, Driving simulator performance in schizophrenia. Schizophr Res. 2005;74(1):121–122.
83.
EdlundMJConradCMorrisP.Accidents among schizophrenic outpatients. Compr Psychiatry. 1989;30(6):522–526.
84.
LaroiFCanlaireJMouradH, Relations between a computerized shopping task and cognitive tests in a group of persons diagnosed with schizophrenia compared with healthy controls. J Int Neuropsychol Soc. 2010;16(1):180–189.
85.
RempferMVHameraEKBrownCE, The relations between cognition and the independent living skill of shopping in people with schizophrenia. Psychiatry Res. 2003;117(2):103–112.
86.
MueserKTBeckerDRWolfeR.Supported employment, job preferences, and job tenure and satisfaction. J Ment Health. 2001;10:411–417.
87.
JohnstoneECMacmillanJFFrithCD, Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry. 1990;157:182–189.
88.
BondGRDrakeREMueserKT, An update on supported employment for people with severe mental illness. Psychiatr Serv. 1997;48(3):335–346.
89.
BondGDietzenLMcGrewJ, Accelerating entry into supported employment for persons with severe psychiatric disabilities. Rehabil Psychol. 1995;40:91–111.
90.
LehmanA.Vocational rehabilitation in schizophrenia. Schizophr Bull. 1995;21:645–656.
91.
Statistics Canada. Canadian Community Mental Health Survey: Mental health and well-being.Ottawa (ON): Statistics Canada; 2003.
92.
McGurkSRMueserKTPascarisA.Cognitive training and supported employment for persons with severe mental illness: One-year results from a randomized controlled trial. Schizophr Bull. 2005;31(4):898–909.
93.
TorreyWCMueserKTMcHugoGH, Self-esteem as an outcome measure in studies of vocational rehabilitation for adults with severe mental illness. Psychiatr Serv. 2000;51(2):229–233.
94.
ArnsPGLinneyJA. Work, self, and life satisfaction for persons with severe and persistent mental disorders. Psychosoc Rehabil J. 1993;17:63–79.
95.
KrupaT.Interventions to improve employment outcomes for workers who experience mental illness. Can J Psychiatry. 2007;52(6):339–345.
96.
MueserKTBeckerDRTorreyWC, Work and nonvocational domains of functioning in persons with severe mental illness: A longitudinal analysis. J Nerv Ment Dis. 1997;185(7):419–426.
97.
HoffmannHKupperZZbindenM, Predicting vocational functioning and outcome in schizophrenia outpatients attending a vocational rehabilitation program. Soc Psychiatry Psychiatr Epidemiol. 2003;38(2):76–82.
98.
NuechterleinKHSubotnikKLGreenMF, Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull. 2011;37(Suppl 2):S33–S40.
99.
SanchezPOjedaNPenaJ, Predictors of longitudinal changes in schizophrenia: The role of processing speed. J Clin Psychiatry. 2009;70(6):888–896.
100.
MilevPHoBCArndtS, Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495–506.
101.
BowieCRMcGurkSRMausbachB, Combined cognitive remediation and functional skills training for schizophrenia: Effects on cognition, functional competence, and real-world behavior. Am J Psychiatry. 2012;169(7):710–718. doi: 10.1176/appi.ajp.2012.11091337.
102.
ToulopoulouTMurrayRM. Verbal memory deficit in patients with schizophrenia: An important future target for treatment. Expert Rev Neurother. 2004;4(1):43–52.
103.
BradfordDWPerkinsDOLiebermanJA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs. 2003;63(21):2265–2283.
104.
LasserRANasrallahHHelldinL, Remission in schizophrenia: Applying recent consensus criteria to refine the concept. Schizophr Res. 2007;96(1–3):223–231.
105.
RevheimNSchechterIKimD, Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. Schizophr Res. 2006;83(2–3):237–245.
